Trial Profile
Phase I-II clinical study for anlotinib in the treatment of brain metastases of non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Aug 2018 New trial record